Condition: Atherosclerosis Cardiovascular Disease · Chronic Kidney Disease · Sponsor: Eli Lilly and Company
The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.
This description comes directly from the study's public registry record.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · 317-615-4559 · LillyTrials@Lilly.com
Physicians interested in becoming principal investigators please contact · clinical_inquiry_hub@lilly.com
Always discuss trial participation with your own doctor first.
| Instituto de Investigaciones Clínicas Bahia Blanca | Bahía Blanca, Argentina | Recruiting |
| CONEXA Investigacion Clinica S.A. | Buenos Aires, Argentina | Recruiting |
| Buenos Aires Macula S.A | Buenos Aires, Argentina | Recruiting |
| CIPREC | Buenos Aires, Argentina | Recruiting |
| Instituto Médico Especializado (IME) | Buenos Aires, Argentina | Recruiting |
| Cicemo Srl | Buenos Aires, Argentina | Recruiting |
| Cardiología Palermo | Buenos Aires, Argentina | Recruiting |
| Consultorio Medico Investigador Principal Dr Besada | Buenos Aires, Argentina | Recruiting |
| Glenny Corp. S.A. | Buenos Aires, Argentina | Recruiting |
| Organizacion Medica de Investigacion | Buenos Aires, Argentina | Recruiting |
| Stat Research S.A. | Buenos Aires, Argentina | Recruiting |
| Investigaciones Medicas Imoba Srl | Buenos Aires, Argentina | Recruiting |
+ 556 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07241390